Eccogene targets $150M in HKEX listing for MASH, obesity drugs

#SITC25: Akeso, Summit’s PD-1xVEGF drug extends life in China lung cancer study

Researchers reported that adding Akeso and Summit Therapeutics’ ivonescimab to chemotherapy cut the risk of death by 26% in a study conducted in China for

Sana suspends work on allogeneic CAR-T; Biokin eyes $387M raise in Hong Kong

Plus, news about Codexis, Gilead, nChroma Bio, Bavarian Nordic, UroGen, Agenus, Accipiter Biosciences and Immunocore: ✂️ Sana trims cell therapy pipeline: The Seattle-based biotech is

ObesityWeek rode the waves of the field’s most dramatic week in months

ATLANTA — At one of the main annual gatherings of researchers and drug developers in the obesity field, Novo Nordisk and Eli Lilly were the

Lilly hires Denali executive to run neuroscience division

Eli Lilly is shaking up its neuroscience and immunology leadership, while giving two longtime executives additional responsibilities. The Indiana-based company said Thursday it has hired

Intellia shares fall after hospitalised CRISPR patient dies

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its clinical trials died.